论文部分内容阅读
目的:分析吉西他滨或培美曲塞联合顺铂治疗晚期非小细胞肺癌的临床疗效和药物安全性。方法:采用随机数字表法将89例晚期非小细胞肺癌患者分为2组,吉西他滨组给予吉西他滨联合顺铂治疗,培美曲塞组给予培美曲塞联合顺铂治疗,均治疗21天为1疗程,2个疗程结束后比较临床疗效和药物安全性。结果:培美曲塞组总缓解率47.73%与吉西他滨组37.78%比较,P>0.05;吉西他滨组胃肠道不良反应发生率64.44%与培美曲塞组56.82%比较,P>0.05;吉西他滨组引起骨髓抑制征象68.89%与培美曲塞组43.18%比较,P<0.05。结论:吉西他滨或培美曲塞联合顺铂治疗晚期NSCLC患者疗效相当,但培美曲塞联合顺铂药物副作用相对较低,在提高服药依从性和改善生存质量等方面具有非常重要的意义。
Objective: To analyze the clinical efficacy and drug safety of gemcitabine or pemetrexed combined with cisplatin in the treatment of advanced non-small cell lung cancer. Methods: 89 cases of advanced non-small cell lung cancer patients were divided into two groups by random number table method, gemcitabine group combined with gemcitabine plus cisplatin, pemetrexed group pemetrexed combined with cisplatin treatment, both for 21 days 1 course of treatment, after two courses of clinical efficacy and drug safety comparison. Results: The total remission rate in pemetrexed group was 47.73% compared with 37.78% in gemcitabine group, P> 0.05. The incidence of gastrointestinal adverse reactions in gemcitabine group was 64.44% compared with 56.82% in pemetrexed group (P> 0.05) 68.89% of the patients with signs of myelosuppression were compared with 43.18% of the pemetrexed group, P <0.05. CONCLUSION: Gemcitabine or pemetrexed combined with cisplatin is effective in treating patients with advanced NSCLC. However, the side effects of pemetrexed combined with cisplatin are relatively low, which is of great significance in improving medication compliance and improving quality of life.